仲裁及其它替代性争议解决方案
About
避重就轻，选择更好的解决方案
飞翰在知识产权争议的初审和上诉方面享有极高声望，但如果情况合适，我们更愿意选择替代性争议解决方案（ADR）。我们经常通过替代性争议解决方案（ADR）而非庭审来制定符合客户要求的诉讼策略。
经验
Represented CSRC in two arbitrations and one litigation relating to exclusive licenses and patent assignments for patents directed to treating Pompe Disease, a rare genetic disorder that is often fatal if untreated. Secured a $180 million settlement from Genzyme.
01-19-0001-6937; 01-20-0000-5081, AAA
Represented a major U.S. pharmaceutical company in two arbitrations concerning a leading biologic. Finnegan’s client won both arbitrations and, in the second, was awarded its attorney fees.
Represented a U.S. pharmaceutical company in an arbitration with a former consultant and inventor. The dispute involved issues relating to inventorship and ownership, as well as the determination of royalties due under various agreements. The matter settled shortly before the hearing on favorable terms.
Member of team that represented AbbVie Biotechnology Ltd. and Abbott GmbH in a WIPO arbitration related to patent licensing.
WIPOA120712, WIPO
Counsel for Cumberland in ANDA litigation and breach of contract arbitration. Successful outcome in bench trial, arbitration, arbitration fee award, and appeal.
16-1155, -1259, Fed. Cir., Judges Moore, Reyna, Taranto
1:12-cv-03846, N.D. Ill., Judge Pallmeyer
Guided Anoto through a successful European arbitration proceeding to enforce a supply agreement for a critical component of Anoto’s products, and then spearheaded a successful effort to enforce the arbitrator’s decision in the United States.
3:16-cv-06209, N.D. Cal., Judge Tigar
